Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.546    -0.034 (-5.86%)
Bid:
0.55
Ask:
0.60
Spread: 0.05 (9.091%)
Market Cap: £3.17m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Blocklisting Interim Review

23 Nov 2015 15:42

RNS Number : 6661G
Futura Medical PLC
23 November 2015
Ā 

23 November 2015

Ā 

Ā 

Ā 

Futura Medical plc

("Futura" or "the Company")

Ā 

Block Listing Update

Ā 

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology announces that, since the last update in May 2015, there have been no changes to the numbers of shares block listed in respect of the Company's two option plans. All ordinary shares of 0.2 pence each.

The table below provides further detail.

Ā 

Name of company:

Futura Medical plc

Name of scheme:

Unapproved Share Option Scheme ("USOS")EMI Share Option Scheme ("EMI")

Ā 

Period of return:

From:

12 May 2015

To:

23 November 2015

Ā 

Number and class of securities not issued under the scheme(s)

USOS:

1,440,600

EMI:

1,394,141

Total:

2,834,741

Ā 

Ā 

Number of securities issued under the scheme(s) during the period

Ā 

Ā 

Number of securities lapsed under the scheme(s) during the period

USOS:

Nil

EMI:

Ā 

Ā 

USOS:

EMI:

Ā 

Ā 

Nil

Ā 

Ā 

Nil

Nil

Ā 

Ā 

Balance under the scheme(s) of securities not yet issued at the end of the period

USOS:

1,440,600

EMI:

1,394,141

Total:

2,834,741

Ā 

Number and class of securities originally admitted and the date of admission

USOS:

814,424 on 25 May 2011 and 1,202,280 on 8 October 2013

USOS Total:

Ā 

2,016,704

EMI:

1,520,576 on 25 May 2011 and 1,467,720 on 8 October 2013

EMI Total:

2,988,296

Total:

5,005,000

Ā 

Ā 

Name of contact:

Derek Martin, Chief Financial Officer

Telephone number of contact:

+44 (0) 1483 685 670

Ā 

Ā 

For further information please contact:

Ā 

Futura Medical plc

Ā 

James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

Email to: james.barder@futuramedical.com

www.futuramedical.com

Ā 

N+1 Singer (Nominated Adviser and Broker)

Ā 

Aubrey Powell / Liz Yong / Tom SmaleCorporate Finance

Ā 

Tel:+44 (0) 20 7496 3000

For media enquiries please contact:

Ā 

Buchanan

Ā 

Mark Court / Sophie Cowles / Stephanie Watson

Tel: +44 (0) 20 7466 5000

Ā 

Ā 

Notes to Editors

Ā 

Futura Medical plc

Ā 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Ā 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

This information is provided by RNS
The company news service from the London Stock Exchange
Ā 
END
Ā 
Ā 
BLREXLFLEFFXFBX
Date   Source Headline
17th Jul 20237:00 amRNSFutura/Haleon Enter US Commercialisation Agreement
30th Jun 20237:00 amRNSFutura Medical - Total Voting Rights
23rd Jun 20234:30 pmRNSRecording of Investor Seminar
22nd Jun 20233:19 pmRNSFutura Medical Annual General Meeting Results
22nd Jun 20237:00 amRNSFutura Medical AGM Statement
19th Jun 202310:25 amRNSCorrection - TR-1: Notification of major holdings
16th Jun 20234:05 pmRNSTR-1: Notification of major holdings
12th Jun 20238:23 amRNSExercise of Warrants
12th Jun 20237:00 amRNSMED3000 Granted US FDA Approval for OTC Sale
8th Jun 20237:00 amRNSFutura Medical Announces Investor Seminar
31st May 20237:00 amRNSBlock Listing Six Monthly Return
26th May 20237:00 amRNSNotice of AGM and availability of Annual Report
24th Apr 20237:00 amRNSTR-1: Notification of major holdings
18th Apr 20237:00 amRNSMED3000, Eroxon® UK Launch
6th Apr 202311:03 amRNSDirectors' / PDMR Dealing and Grant of Options
5th Apr 20237:00 amRNSFull Year Results ended 31 December 2022
29th Mar 20237:00 amRNSUpdate on MED3000 regulatory approval in the US
27th Mar 20235:24 pmRNSNotice of Preliminary Results 2022
14th Mar 20238:33 amRNSMED3000 commercial and US regulatory update
15th Feb 20237:00 amRNSMED3000 FM71 Presentation at ESSM Congress 2023
1st Feb 20231:26 pmRNSBlock Listing Applications to AIM
26th Jan 20237:00 amRNSPre-launch of MED3000 ahead of H1 2023 launch
12th Jan 202311:09 amRNSFutura Remuneration, Options & Total Voting Rights
15th Dec 20223:01 pmRNSTR-1: Notification of major holdings
13th Dec 20221:10 pmEQSFutura Medical 'on track' for launch in H1 2023
13th Dec 20227:00 amRNSFutura Medical announce milestone year for MED3000
30th Nov 20227:00 amRNSFutura Block Listing Six Monthly Return
30th Nov 20227:00 amRNSTotal Voting Rights
21st Oct 20224:40 pmRNSSecond Price Monitoring Extn
21st Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 202212:25 pmRNSTR-1: Notification of major holdings
4th Oct 20225:31 pmRNSTotal Voting Rights
3rd Oct 20227:00 amRNSApplication to the US FDA for MED3000
16th Sep 20229:57 amRNSPDMR Dealing and Total Voting Rights
13th Sep 20227:00 amRNSFutura Medical Interim Results 2022
1st Sep 20227:00 amRNSNotice of Interim Results
31st Aug 20227:00 amRNSHighly positive FM71 Phase 3 Study Results
12th Jul 20224:41 pmRNSSecond Price Monitoring Extn
12th Jul 20224:35 pmRNSPrice Monitoring Extension
28th Jun 20223:58 pmRNSFutura Medical AGM Results
28th Jun 20227:00 amRNSFutura Medical AGM Statement
7th Jun 20221:33 pmRNSTR-1: Notification of major holdings
1st Jun 20227:00 amRNSNotice of AGM and Availability of Annual Report
31st May 20227:00 amRNSBlock Listing Six Monthly Return
24th May 202211:40 amRNSTR-1: Notification of major holdings
23rd May 202210:35 amRNSAgreement with Cooper Consumer Health - Correction
23rd May 20227:00 amRNSMED3000 Collaboration in EEA, UK & Switzerland
17th May 20223:56 pmRNSTR-1: Notification of major holdings
16th May 20222:51 pmRNSTR-1: Notification of major holdings
13th May 202212:12 pmRNSTR-1: Notification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.